Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 2
2007 3
2008 5
2009 2
2010 2
2011 4
2012 4
2013 2
2014 3
2015 6
2016 13
2017 7
2018 4
2019 1
2020 2
2021 6
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Ferolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Marconcini R, Giuffrida D, Amoroso V, La Salvia A, Vaccaro V, Faggiano A, Colao A, Volante M, Ghizzoni S, Mazzanti P, Houchard A, Fazio N. Ferolla P, et al. Neuroendocrinology. 2023;113(3):332-342. doi: 10.1159/000526811. Epub 2022 Aug 31. Neuroendocrinology. 2023. PMID: 36044870 Clinical Trial.
Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451].
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Baudin E, et al. Among authors: ferolla p. Ann Oncol. 2021 Nov;32(11):1453-1455. doi: 10.1016/j.annonc.2021.08.2150. Epub 2021 Sep 29. Ann Oncol. 2021. PMID: 34598840 Free article. No abstract available.
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer.
Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. Partelli S, et al. Among authors: ferolla p. Cancer Treat Rev. 2021 Sep;99:102208. doi: 10.1016/j.ctrv.2021.102208. Epub 2021 Apr 20. Cancer Treat Rev. 2021. PMID: 34238640 Review.
Effect of EPA on Neonatal Pig Sertoli Cells "In Vitro": A Possible Treatment to Help Maintain Fertility in Pre-Pubertal Boys Undergoing Treatment With Gonado-Toxic Therapies.
Arato I, Ceccarelli V, Mancuso F, Bellucci C, Lilli C, Ferolla P, Perruccio K, D'Arpino A, Aglietti MC, Calafiore R, Cameron DF, Calvitti M, Baroni T, Vecchini A, Luca G. Arato I, et al. Among authors: ferolla p. Front Endocrinol (Lausanne). 2021 May 20;12:694796. doi: 10.3389/fendo.2021.694796. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34093450 Free PMC article.
Prognostic Significance of Pulmonary Multifocal Neuroendocrine Proliferation With Typical Carcinoid.
Tassi V, Scarnecchia E, Ferolla P, Mete O, Manjula M, Allison F, Potenza R, Vannucci J, Ceccarelli S, Yasufuku K, De Perrot M, Pierre A, Darling G, Colella R, Ascani S, Mattioli S, Keshavjee S, Waddell TK, Puma F, Daddi N. Tassi V, et al. Among authors: ferolla p. Ann Thorac Surg. 2022 Mar;113(3):966-974. doi: 10.1016/j.athoracsur.2021.03.069. Epub 2021 Apr 5. Ann Thorac Surg. 2022. PMID: 33831394
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆.
Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Baudin E, et al. Among authors: ferolla p. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Ann Oncol. 2021. PMID: 33482246 Free article. No abstract available.
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).
Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. Panzuto F, et al. Among authors: ferolla p. J Endocrinol Invest. 2021 May;44(5):989-994. doi: 10.1007/s40618-020-01393-4. Epub 2020 Aug 16. J Endocrinol Invest. 2021. PMID: 32803662 Free PMC article.
Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.
Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA). Leyden S, et al. Among authors: ferolla p. Int J Cancer. 2020 Mar 1;146(5):1316-1323. doi: 10.1002/ijc.32678. Epub 2019 Oct 25. Int J Cancer. 2020. PMID: 31509608 Free PMC article.
Correction to: Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database.
Marini F, Giusti F, Fossi C, Cioppi F, Cianferotti L, Masi L, Boaretto F, Zovato S, Cetani F, Colao A, Davì MV, Faggiano A, Fanciulli G, Ferolla P, Ferone D, Loli P, Mantero F, Marcocci C, Opocher G, Beck-Peccoz P, Persani L, Scillitani A, Guizzardi F, Spada A, Tomassetti P, Tonelli F, Brandi ML. Marini F, et al. Among authors: ferolla p. Endocrine. 2018 Oct;62(1):234-241. doi: 10.1007/s12020-018-1668-3. Endocrine. 2018. PMID: 30032405
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A. Faggiano A, et al. Among authors: ferolla p. Endocrine. 2018 Oct;62(1):46-56. doi: 10.1007/s12020-018-1583-7. Epub 2018 Mar 23. Endocrine. 2018. PMID: 29572709
57 results